Last week, MLC's two‑day strategic session became an important turning point in the project.
The global MLC project is progressing on multiple continents simultaneously, with the team spread across different countries for most of the time. The in‑person meeting added a new dimension to strategic discussions and roadmap planning.
Key milestone: all co‑founders took part in an in‑house testing focus group. Each team member has begun using the CGM Flystat continuous glucose monitor and will keep it on for 15 days. The mobile application will log all results, allowing users to confirm that the device is correctly configured, the readings are reliable, and the suggested recommendations are appropriate.
It's a unique honour to wear a sensor born out of the MLC project.
Day two brought together the co‑founders with R&D representatives and the certification team. The session addressed ongoing work items, assessed the data gathered, and established a common understanding of the certification roadmap and the outcomes of the first production-audit stage.
Solid progress has been confirmed: the project remains on plan, the team is collaborating effectively, and the product is passing critical checkpoints en route to market launch.
MLC is steadily progressing backed by its team, its product, and a clear vision of what lies ahead.
